Why Does Arena Pharmaceuticals, Inc. (ARNA)'s Obesity Drug Have Abuse Potential?
5/13/2013 7:15:26 AM
More...
|
BIOCOM Applauds Arena Pharmaceuticals, Inc. (ARNA)' Commitment to Innovation, Contributions to Southern California Life Science Community
5/10/2013 9:23:36 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) to Present at the Bank of America (BAC) Merrill Lynch 2013 Health Care Conference
5/10/2013 7:26:05 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) Pockets $65 Million From Partner Eisai Inc. (ESALF.PK) After Belviq Approval
5/8/2013 7:40:26 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) Withdraws Diet Drug Application in Europe
5/3/2013 7:57:48 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) Provides Corporate Update and Reports First Quarter 2013 Financial Results
5/3/2013 7:11:20 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
4/26/2013 7:54:27 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
4/5/2013 9:29:28 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) Announces Eisai Inc. (ESALF.PK)'s Submission of BELVIQ® (lorcaserin HCl) Marketing Authorization Application in Mexico
4/1/2013 9:46:35 AM
More...
|
Arena Pharmaceuticals, Inc. (ARNA) Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
3/4/2013 10:42:14 AM
More...
|
|